Abstract 117P
Background
Hepatoid adenocarcinoma of stomach (HAS) is a rare subtype of gastric cancer (GC) with hepatocyte-like differentiation and a dismal prognosis. Although HAS has different histological and molecular properties and more aggressive biological behavior, most patients with HAS still receive the same regimen as usual GC. A comprehensive understanding of the molecular properties of HAS may provide insights into personalized diagnosis and treatment, however, this area is under-studied.
Methods
We aimed to explore methylome and transcriptome profiling of HAS in a relatively precise scenario. The laser capture microdissection (LCM) was used to isolate thirty-two formalin fixed paraffin-embedded (FFPE) tissue into gastric adenocarcinoma section (GAC) and hepatocellular-like section (HAS). According to the manufacturer's protocol, DNA-associated methylation sequencing and RNA-associated transcriptome sequencing were performed.
Results
With Laser-Capture Microdissection (LCM) technique, we separate HAS FFPE sample into gastric adenocarcinoma component (GAC) and HAS component. The whole genome RNAseq and methylation sequencing (GMseq) were used to explore HAS expression patterns and methylation modification profile. We found that differentially methylated cytosine was effective in distinguishing GAC from HAS, and stem cell-related gene expression and pathway enrichment were higher in GAC than in HAS. Correspondingly, HAS showed TNFSF15 gene significantly hypermethylation and lower expression features. In addition, in vivo xenograft models derived from TNFSF15 knockout cells showed higher aggressiveness and hepatocyte-like gene expression. Our study sheds light on the critical role of TNFSF15 in HAS transdifferentiation, and intervening methylation of TNFSF15 may be a clinical option to improve prognosis and reduce metastasis.
Conclusions
In summary, we found that the GAC component has the expression features of pluripotent stem cells and mesothelial cells, and the HAS component has the features of hepatoblast and mature hepatocytes. We propose that GAC mesoderm and endoderm dedifferentiation bias TME as the key role to HAS transdifferentiation and TNFSF15 may be a key regulatory factor in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial
Presenter: Yucheng Dong
Session: Poster session 08
103P - Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection
Presenter: Yadong Wang
Session: Poster session 08
104P - The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
Presenter: Laura Bonanno
Session: Poster session 08
105P - Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Presenter: Luís Leite
Session: Poster session 08
106P - Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
Presenter: Laura Bonanno
Session: Poster session 08
107P - Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors
Presenter: Takeshi Kuwata
Session: Poster session 08
108P - Assessing molecular characteristics in a large cohort of anal squamous cell carcinoma patients
Presenter: Cristina Smolenschi
Session: Poster session 08
109P - Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma
Presenter: Elisabeth Ashton
Session: Poster session 08
110P - 13-plex non-invasive genotyping in HPV related cancers in the MOSCATO trial
Presenter: Elise Rupp
Session: Poster session 08
111P - Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies
Presenter: Veronique Debien
Session: Poster session 08